Decision points for the initiation of systemic treatment for psoriasis - 21/08/11
, John Y.M. Koo, MD b, Alan Menter, MD c, Jerry Bagel, MD d
Correspondence to: Steven Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071.Winston-Salem, North Carolina; San Francisco, California; Dallas, Texas; and East Windsor, New Jersey
Abstract |
Psoriasis has a tremendous effect on health-related quality of life. Phototherapy and systemic treatments are used for patients with more debilitating (physically and emotionally) forms of the disease. These treatments can be extremely effective but can also have potentially significant adverse effects. The decision to undertake systemic treatment of psoriasis is a complex one that requires both experience and judgment. With the recent advent of new biologic systemic drugs for moderate to severe psoriasis, the need to clarify patient candidates for systemic therapy has become very important. Here, we present a diagnostic algorithm and a formal measure, the Koo–Menter Psoriasis Instrument (KMPI), to aid in identifying patients that would benefit from systemic therapy. In addition, the KMPI can be used to document and justify treatment decisions for health care payers. While the decision to undertake systemic treatment and the choice of specific treatment plan must ultimately be made mutually by the patient and physician, these tools are designed to provide information that will be valuable in these determinations.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Disclosure: Dr Feldman has received grant and other support from Biogen, Amgen, Genentech, Roche, and Centocor. Dr Koo has received grant or other support from Allergan, Amgen, Biogen, Centocor, Fujisawa, Genentech, ICN, Novartis, and Roche. Dr Menter has received grant or other support from Abbott, Allergan, Amgen, Biogen, Centocor, Genentech, Novartis, Serona, and Xoma. Dr Bagel has received educational grants from Amgen, Biogen, Genentech and Novartis, and has been a speaker supported by Biogen. Presented as a poster at the 2003 International Psoriasis Symposium, June 18/22, 2003, New York, NY, and at the 2003 Summer Meeting of the American Academy of Dermatology, July 25-29, 2003, Chicago, Ill. This manuscript was reviewed by the Medical Board of the National Psoriasis Foundation and was endorsed by a majority vote. Reprints not available from the authors. |
Vol 53 - N° 1
P. 101-107 - juillet 2005 Retour au numéro
Article précédent
- Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: A report of 5 cases and assessment of the literature and diagnostic criteria
- Whitney A. High, David Stewart, Christopher R.H. Wilbers, Clay J. Cockerell, Mai P. Hoang, James E. Fitzpatrick
- B-RAF and melanocytic neoplasia
- Melissa Gill, Julide Tok Celebi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?